Financial News

Eli Lilly and Company (NYSE: LLY) today announced agreements to acquire three companies, Curevo Inc. (Curevo), LimmaTech Biologics AG (LimmaTech Biologics), and Vaccine Company, Inc. (Vaccine Company), that expand

https://www.wsj.com/business/deals/lilly-agrees-to-buys-trio-of-vaccine-developers-cd5d50fa

LLY's stock is still down year-to-date as AI-driven narratives have captured the bulk of investor attention and capital in 2026.

Chamath Palihapitiya reacted on X after Eli Lilly's VERVE-102 showed strong Phase 1b LDL cholesterol reduction results.

It may be too late for Viking to take on the "dark horse" role in the GLP-1 wars.

The efficacy of Eli Lilly's new, still-in-development GLP-1 drug is gaining attention, but don't forget its older GLP-1 drugs just yet.

Eli Lilly and Co (NYSE:LLY) last week reported late-stage weight loss data for retatrutide, which UBS analysts highlighted showed “solid strong weight loss efficacy” and were broadly in line with expectations ahead of further detail at the American Diabetes Association meeting. UBS...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

The Vanguard Dividend Appreciation Index Fund ETF Shares (NYSEARCA:VIG) is having a quieter year than its big-cap dividend-growth reputation suggests, with shares around $229 and a 5% year-to-date gain trailing the broader market. The 12-month picture is stronger at almost 17%, but the recent flattening tells you something important: VIG’s dividend-growth playbook is being squeezed ... VIG Investors: Watch the 10-Year Treasury Yield This Week—4.75% Is the Danger Line

Eli Lilly and Company (NYSE: LLY) today announced positive Phase 1b Heart-2 study results for VERVE-102, an investigational in vivo base editing medicine designed to durably turn off the PCSK9 gene in the liver and lower blood low-density lipoprotein cholesterol (LDL-C) following a single infusion. The Heart-2 trial is evaluating VERVE-102 in adults with heterozygous familial hypercholesterolemia (HeFH) or premature coronary artery disease (CAD). These data were presented as a late-breaking oral

In the Phase 1b Heart-2 trial, a single intravenous infusion of VERVE-102 produced dose-dependent lowering of PCSK9 and LDL-C, with both reductions sustained over follow-up of up to 18 months in participants at high risk for cardiovascular disease

The pharma giant is taking steps to expand its portfolio.

With a 5-year dividend growth rate of 15.23%, Eli Lilly and Company (NYSE:LLY) is included among the 10 Best Dividend Growth Stocks to Buy and Hold for 3 Years. In a CNBC report published on May 21, Eli Lilly and Company (NYSE:LLY) said its experimental obesity drug, retatrutide, cleared a major late-stage clinical trial. The results […]

Go beyond the broad index and find which segment of healthcare best suits your portfolio needs now.

This breakdown considers whether Eli Lilly at around US$1,065 a share may still offer value or whether the best of the opportunity may already be behind it, with a focus on what the current price might imply. Over the short term, the stock has returned 6.0% over the past week and 15.6% over the past month. Year to date it is down 1.4%, and the 1 year return stands at 50.3%, with a very large gain over 5 years of around 7x. Recent headlines have centered on Eli Lilly's role in large scale...

Eli Lilly and Company (NYSE:LLY) is one of the best low risk stocks to buy in 2026. On May 21, Lilly’s Phase 3 TRIUMPH-1 trial evaluated retatrutide, an investigational once-weekly triple hormone receptor agonist (GIP/GLP-1/glucagon). The 80-week study involved 2,339 adults with obesity or overweight and at least one comorbidity, excluding diabetes. All doses met […]

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.

Stocks were up sharply to end the week as NVIDIA’s forward guidance showed tangible demand to support AI infrastructure and overshadowed mixed retail reports

Eli Lilly (LLY) delivered impressive late-stage trial results for its newest weight-loss drug. UBS Global head of biotech research Michael Yee explains what this means for Novo Nordisk (NVO) and the future of the industry.

Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index advancing 1.1% and the

Novo Nordisk (NYSE:NVO) has entered a partnership with OpenAI to apply artificial intelligence across drug discovery, manufacturing, and supply chain operations. The company is preparing a global rollout of the oral Wegovy weight loss pill after its US launch. Recent trial data for semaglutide and pipeline drugs such as Amycretin and CagriSema indicate further progress in obesity and metabolic disease treatments. Novo Nordisk is drawing fresh attention as it pairs an AI push with a growing...

Healthcare stocks rose Friday afternoon, with the NYSE Healthcare Index advancing 0.8% and the State

Amgen stock could offer attractive long-term upside for investors willing to ride through near-term volatility.

Citi said Eli Lilly and Co's (NYSE:LLY) experimental obesity drug retatrutide has set a new competitive benchmark for the GLP-1 weight-loss market after a pivotal trial showed patients losing 28% of their body weight over 80 weeks at the highest dose. The results from the TRIUMPH-1 trial, the...

Eli Lilly's retatrutide delivers its third phase III win, showing up to 28.3% weight loss at 80 weeks and broader gains across obesity-related measures.

CNBC's Kelly Evans discusses the potential of OpenAI's anticipated $1 trillion IPO and what investors may be able to expect with Erica Brescia of Redpoint Ventures.

Eli Lilly (LLY) said Friday that a new analysis from two phase 3 trials showed that its GLP-1 pill F

CNBC's Megan Cassella reports on the highlights from the swearing in of Federal Reserve chairman Kevin Warsh at the White House.

(Updates with Novo Nordisk's response in the fourth paragraph.) Novo Nordisk's (NVO) Ozempic and